SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood (HOOD) is trending after announcing its inclusion in the S&P 500, driving significant discussion about its growth as a platform and potential for further expansion. The community is buzzing about the stock's potential and the upcoming product summit. Some are speculating on new features and banking services, while others are debating the stock's valuation and possible short-term pullbacks.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending amid discussions about a special warrant dividend for shareholders and its potential impact on short sellers. The community is analyzing the implications of the warrants, speculating on a possible short squeeze, and debating the company's financial strategy under its current leadership. Some traders are closely watching for any announcements from Roaring Kitty.

Asset Entities, Inc. engages in providing social media marketing and content delivery services. It offers its services to Discord, TikTok, and other social media platforms. It also designs, develops and manages servers for communities on Discord. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani and Kyle Fairbanks on August 1, 2020 and is headquartered in Dallas, TX.

Asset Entities Inc - Ordinary Shares - Class B

Asset Entities Inc.

Asset Entities Inc. ($ASST) is trending due to its upcoming merger with Strive Enterprises and potential for a Bitcoin treasury, sparking comparisons to other high-flying crypto plays. The community is focused on a potential short squeeze, citing high short interest and cost to borrow, with some anticipating a significant price increase. Discussions also involve the involvement of prominent investors and the potential impact of the merger on the company's valuation and treasury strategy.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle's stock is surging following reports of substantial cloud infrastructure growth and a massive increase in remaining performance obligations driven by large AI contracts, despite mixed earnings. The community is buzzing about the company's future revenue potential and multi-billion dollar deals, with some questioning the aggressive growth forecasts, while others view it as a long-term AI play.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

AAPL is trending as the community reacts to the latest product announcements, including the new iPhone 17 and AirPod updates. While some express excitement over design improvements and features like live translation, others voice concerns about a lack of significant innovation and AI integration, leading to a mixed sentiment around the stock's near-term prospects. Discussions also include the potential impact of external factors like tariffs and overall market conditions.

Armada Acquisition Corp. I operates as a blank check company. It was formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. The company was founded on November 5, 2020 and is headquartered in Philadelphia, PA.

Rezolve AI PLC .

Rezolve AI Limited

Rezolve AI (RZLV) is trending as investors discuss institutional buying and potential buyouts from major tech companies, fueling optimism. Community members are highlighting the company's fundamentals, partnerships with Microsoft and Google, and the upcoming earnings report. There's also discussion around a General Meeting of Shareholders set for September 30, 2025, that will address the company's adoption of the annual accounts and Director's Report for 2024.

QMMM Holdings Ltd. engages in the provision of digital advertising services. It offers interactive design, animation, art-tech and virtual technologies used in commercial campaigns. It has worked with domestic and international banks, real estate developers, amusement parks, international sports apparel, footwear brands, luxury cosmetic products, and international brands. The company was founded by Bun Kwai on July 29, 2022 and is headquartered in Hong Kong.

QMMM Holdings Ltd. - Ordinary Shares - Class A

QMMM Holdings Ltd.

QMMM is trending due to community discussion around its significant price volatility, drawing comparisons to other stocks with recent unexpected surges. The stock's movement is attributed to its announcement of a new cryptocurrency treasury strategy, sparking interest and speculation. Some traders are pointing to the potential for pump-and-dump schemes, while others are looking for the next stock to mirror QMMM's performance.

ONDO is a DeFi primitive that enables users to originate risk-isolated, fixed yield loans backed by yield-generating crypto-assets. It's unique because it's a permissionless protocol that allows users to interact on a peer-to-pool basis with no intermediaries.

Ondo

ONDO is trending as the community discusses its potential in the Real World Asset (RWA) tokenization space, particularly with the recent launch of tokenized U.S. stocks and ETFs. Community members are speculating on partnerships, potential market caps, and entry points, while acknowledging that it may take time for the market to give green lights. BlackRock's involvement and tokenization of assets are also hot topics.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

$DOG.X is trending as community members highlight its strong connection to Bitcoin, being built on the Runes protocol, and its fair launch with no insiders or VC allocation, sparking discussions about its potential to disrupt the meme coin landscape. The community emphasizes that $DOG.X secures the Bitcoin network through transaction fees and promotes a culture-driven movement, leading to accumulation.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is trending due to a mix of factors, including discussions around data center growth fueled by AI and partnerships, such as the deal with $NBIS. Community members are debating whether the stock is overvalued, while also analyzing its potential based on AI advancements and recent earnings from related companies like Oracle. There's also discussion around technical levels, potential shorting opportunities, and analyst ratings.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cathie Wood Loves This Under-the-Radar AI Stock. Is It Time for You to Buy Now?

The popular investor poured $366.2 million in the company’s shares to carry out her latest purchase.

Shares of Tempus AI, Inc. were volatile Tuesday, surging to highs last seen in mid-November before paring gains to trade slightly higher.Trading volume was nearly double the daily average as the healthcare tech firm confirmed it will report fourth-quarter and full-year 2024 earnings on Feb. 24, with a conference call at 4:30 p.m. ET.Wall Street expects the company to report an adjusted loss of $0.16 per share on revenue of $203.12 million.Retail sentiment on Stocktwits remained ‘bullish,’ though the score read slightly lower than last week following insider selling.&nbsp;<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/TEM_sentiment_and_message_volume_Feb_11_564e2ba31d.png" alt="TEM sentiment and message volume Feb 11.png" width="1318" height="324"><figcaption>TEM sentiment and message volume Feb 11 as of 11:45 am ET | source: Stocktwits</figcaption></figure>CEO and Chairman Eric Lefkofsky recently sold nearly 240,000 shares between Feb. 5-7, netting over $16.2 million, while CFO Jim Rogers sold 8,712 shares for $588,669, as per SEC filings.Stocktwits users had mixed reactions. One trader noted the stock “gave back most of the pump,” suggesting weak holding interest amid short pressure.&nbsp;Another pointed to a bullish technical setup, predicting a move toward $80.<stembedurl>https://stocktwits.com/phijammaslamma/message/603757859</stembedurl><stembedurl>https://stocktwits.com/CoBear/message/603746559</stembedurl>Tempus AI has gained a lot of&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tem-stock-heads-for-best-rally-in-5-months/chb9WlYR8z">attention</a> since launching an AI-enabled personal health app last month.But it also made headlines after former House Speaker Nancy Pelosi purchased 50 call options in the stock, a trade closely watched by retail investors.Last week, the company announced the completion of its $600 million acquisition of Ambry Genetics.&nbsp;TD Cowen reportedly believes the acquisition strengthens Tempus with a $300-million profitable lab, enhances product offerings, and accelerates its path to positive free cash flow.The research firm, however, thinks Ambry’s slower growth is a concern.Tempus AI stock has surged over 70% since its June 2024 IPO, with its Stocktwits following up nearly 700% in three months.&nbsp;Short interest has also climbed from 3.9% at the start of 2025 to 7.3% by the end of January, per Koyfin data.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration logo of Tempus AI is seen on a smartphone against a screen displaying a trade markets illustration on April 15, 2024 in Krakow, Poland. 

Tempus AI Stock Swings Wildly As Earnings Near, Retail’s Cautiously Optimistic After Insider Sales 

The company has gained a lot of attention since launching an AI-enabled personal health app last month.

Equity

Cathie Wood Just Doubled Down on This AI Stock. Should You?

The stock is one of the renowned investor’s top holdings.

Intellia Therapeutics, Inc. shares declined over 5% on Monday morning after Morgan Stanley downgraded the stock to ‘Equal Weight’ from ‘Overweight,’ slashing its price target from $56 to $11.&nbsp;The downgrade and what the brokerage says is a broader lack of catalysts for the year dented retail sentiment, with conversations on Stocktwits turning more skeptical.Morgan Stanley cited a “more measured launch” for nexiguran ziclumeran, Intellia’s lead therapy for transthyretin amyloidosis, a rare and progressive heart disorder.&nbsp;The brokerage also pointed to the company’s recent discontinuation of its NTLA-3001 program for alpha-1 antitrypsin deficiency-associated lung disease, reducing near-term growth prospects.The analyst noted growing competition from non-gene-editing therapies, which could challenge Intellia’s position as a leader in “in vivo” CRISPR editing.&nbsp;Intellia’s approach reportedly delivers CRISPR components directly into the body to modify DNA, bypassing the need to engineer treatments from a patient’s cells.Earlier this month, Intellia announced a 27% workforce reduction and plans to halt&nbsp;the development of NTLA-3001 and some early-stage research programs.The company expects to incur $8 million in restructuring charges in the first quarter but believes the changes, combined with its cash balance of $862 million at the end of the fourth quarter, will extend its cash runway into the first half of 2027.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/NTLA_sentiment_and_message_volume_Jan_27_414be9f90a.png" alt="NTLA sentiment and message volume Jan 27.png" width="1318" height="324"><figcaption>NTLA sentiment and message volume Jan 27 as of 11:40 am ET | source: Stocktwits</figcaption></figure>Retail sentiment on Stocktwits turned more ‘bearish’ following the downgrade.&nbsp;<stembedurl>https://stocktwits.com/KimAntony/message/601612137</stembedurl><stembedurl>https://stocktwits.com/CharlesEscobar/message/601578564</stembedurl><a href="https://stocktwits.com/symbol/NTLA">Intellia’s stock</a> has a high short interest of 21.3% and has lost nearly 60% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Intellia Stock Dips After Morgan Stanley Downgrade, Retail Sentiment Weakens

The brokerage pointed to the company’s recent discontinuation of its NTLA-3001 program for alpha-1 antitrypsin deficiency-associated lung disease, reducing near-term growth prospects.

Shares of Tempus AI climbed more than 5% on Thursday afternoon, poised for their longest winning streak since August 2024.&nbsp;The healthcare technology company has surged from $35 to $53 in just three days, drawing significant retail attention.On Tuesday, Tempus&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tempus-ai-stock-surges-on-ai-enabled-healthcare-app-launch-pelosi-buy/chbdxNURFV">introduced</a> an artificial intelligence-powered healthcare concierge app for patients, sparking optimism about its potential in the growing AI healthcare space.A routine stock trading disclosure revealed former House Speaker Nancy Pelosi purchased 50 call options on Tempus, expiring in January 2026 with a $20 strike price. This added to the speculative excitement surrounding the stock.President Donald Trump’s announcement of “Stargate,” a joint venture with OpenAI, Oracle, and SoftBank to invest billions in domestic AI development, further fueled investor enthusiasm for AI-related stocks like Tempus.While Tempus managed to see a 186% growth in retail followers on Stocktwits since Tuesday, sentiment shifted from ‘extremely bullish’ to ‘bearish’ by Thursday afternoon.&nbsp;The platform saw a spike in pessimistic messages, with users criticizing the frenzy over Pelosi’s involvement and some reporting profit-taking after the stock’s rally.<stembedurl>https://stocktwits.com/WallStreetBetzBoss/message/601130338</stembedurl><stembedurl>https://stocktwits.com/HIGHTABLETRADES/message/601134687</stembedurl><stembedurl>https://stocktwits.com/Harvz90/message/601192109</stembedurl>A regulatory filing from Wednesday night disclosed that Tempus AI founder and CEO Eric Lefkofsky sold 946,084 shares of Tempus between Jan. 15-17.&nbsp;That caused a brief dip in the stock earlier on Thursday, although it rebounded later in the session.Tempus AI has a short interest of 5.5%, according to Koyfin data.Shares of the company have gained over 33% in the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration logo of Tempus AI is seen on a smartphone against a screen displaying a trade markets illustration on April 15, 2024 in Krakow, Poland. (Photo by Dominika Zarzycka/NurPhoto via Getty Images)

Tempus AI Stock Eyes Best Rally In 5 Months Amid Pelosi-Linked Hype, But Retail’s Turning Doubtful Now

A regulatory filing from Wednesday night disclosed that Tempus AI founder and CEO Eric Lefkofsky sold 946,084 shares of Tempus between Jan. 15-17.

Options Alert: Should Investors Jump on This Cathie Wood-Owned Life Sciences Specialist?

While proteomics firms Quantum-Si has made waves recently, QSI stock might not be the long-term play value investors are seeking.

Intellia Therapeutics, Inc. ($NTLA) shares plunged hard on Thursday after the small-cap, clinical-stage biotech reported results from mid-stage study results of its CRISPR-based gene-editing therapy codenamed NTLA-2002 in patients with hereditary angioedema (HAE).HAE is a rare genetic disorder that manifests as severe, recurring and unpredictable inflammatory attacks in various organs and tissues of the body. The condition could lead to potentially life-threatening swelling attacks.&nbsp;The disorder has no curative therapies but current preventive therapies have to be administered lifelong.&nbsp;Intellia said the results from the Phase 2 study showed NTLA-2002 has the potential to eliminate HAE attacks following a one-time infusion.&nbsp;Among the findings from the study are:<ul><li>Both dose levels tested (25 mg and 50 mg) reduced mean monthly attacks, with the latter dose resulting in a 77% reduction during weeks 1-16 and 81% reduction in weeks 5-16.</li><li>Eight of the 11 patients in the 50 mg arm were completely attack free following one-time infusion</li><li>Safety and tolerability profiles were encouraging.</li></ul>“We are highly encouraged by these results, which we believe sets NTLA-2002 apart from other prophylaxis treatments. What was previously an unimaginable potential to be free of chronic therapy is one step closer to becoming a reality for the HAE community,” said John Leonard, CEO of Intellia.The company said it has selected the 50 mg formulation for evaluation in the global Phase 3 study dubbed ‘HALEO.’ Screening for the study is currently ongoing, it said.HAE therapeutics market was at $4.1 billion in 2023 and is estimated to grow at 9.2% compounded annual growth rate between 2024 and 2032,<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.gminsights.com/industry-analysis/hereditary-angioedema-therapeutics-market"> according</a> to Global Market Insights.The negative reaction could be due to the “buy-the-rumor, sell-the-news” phenomenon as the stock tacked on about 17%&nbsp;gains from a near-term (Oct. 10) low of $17.09.<figure class="image"><a href="https://stocktwits.com/symbol/NTLA"><img style="aspect-ratio:633/142;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/intellia_sentiment_b2935066a6.png" alt="intellia-sentiment.png" width="633" height="142"></a><figcaption>NTLA sentiment and message volume October 24, 2024, as of 11:05 am ET | Source:&nbsp;Stocktwits</figcaption></figure>On Stocktwits, retail trader sentiment was ‘extremely bearish’ (21/100), reversing from ‘bullish’ mood a day ago, with message volume spiking to ‘extremely high.’At 11:05 am ET, the stock was down 19.51% at $16.05, although off the day’s low of $15.52, which marked the lowest level in over four years.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ups-earnings-and-revenue-beat-estimates/cJ218XiR7Q">UPS Stock Soars Pre-Market, Keeps Retail Bullish As Q3 Beat Pleases Wall Street</a>For updates and corrections email newsroom@stocktwits.com

Intellia's mid-stage gene-editing therapy study results did not impress investors.

Intellia Stock Plunges To 4-Year Low Despite Promising Mid-Stage Study Results For Rare Genetic Disorder Therapy, Retail Sentiment Dips

Intellia stock tumbled to its lowest level in over four years as investors shrugged off what the company touted as promising results for its hereditary angioedema investigational gene-editing therapy.

Shares of Moderna plunged nearly 17% during the pre-market session after the company trimmed its full-year forecast. It cited low EU sales in 2024, potential revenue deferrals for certain international sales into 2025, and an increasingly competitive environment for respiratory vaccines in the U.S.Moderna now expects 2024 net product sales between $3.00 billion and $3.50 billion from its respiratory franchise compared to previous guidance of $4 billion.Following the announcement, retail sentiment dipped into ‘extremely bearish’ territory (16/100) souring further from yesterday’s ‘bearish’ reading.<figure class="image"><a href="https://stocktwits.com/symbol/MRNA"><img style="aspect-ratio:786/224;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_08_01_at_9_33_23_AM_44abb6c210.png" alt="Moderna sentiment meter as of 8:47 a.m. on August 01, 2024" width="786" height="224"></a><figcaption>Moderna sentiment meter as of 8:47 a.m. on August 01, 2024</figcaption></figure>On a positive note, the vaccine-maker reported an earnings loss of $3.33 during the second quarter versus an estimated loss of $3.39. Revenue came in at $241 million compared to a forecast of $132 million. Despite beating the analyst estimate, revenue declined 30% year-over-year (YoY) weighed down by decreased sales of the company's COVID-19 vaccine.Stéphane Bancel, Chief Executive Officer of Moderna stated that the firm has significantly lowered its operating costs during the second quarter. “We remain focused on execution for the 2024-25 COVID season and the launch of our RSV vaccine in the U.S.,” he said.Bancel stated the firm is involved in discussions with governments across Europe but some of them have pointed toward a tight budget restraining their capacity to buy more vaccines. The firm reportedly expects to see sales growth by 2025 and hit a breakeven position by 2026.Retail investors aren’t happy with the full-year guidance trim and the company’s efforts on the Covid vaccine given that its demand remains uncertain. One Stocktwits user expressed his ‘bearish’ view by stating that Moderna lowered its already lowered guidance, a sign it still has work to do in sufficiently diversifying its revenue streams.<figure class="image"><a href="https://stocktwits.com/JonOliNYC2020/message/581403885"><img style="aspect-ratio:794/160;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_08_01_at_9_34_35_AM_028dd1393e.png" alt="Stocktwits user JonOliNYC2020's post on Moderna stock " width="794" height="160"></a><figcaption>Stocktwits user JonOliNYC2020's post on Moderna stock&nbsp;</figcaption></figure>

Moderna now expects 2024 net product sales between $3.00 billion and $3.50 billion

Moderna Surpassed Q2 Earnings Estimates: Here’s Why Retail Sentiment Is ‘Extremely Bearish’ And The Stock Is Down 17%

While the vaccine-maker’s revenues beat estimates and its loss narrowed, management slashed its full-year sales forecast. Moreover, its struggles with EU sales and uncertainty over COVID vaccine demand remain key concerns for investors.

ARKG
ARK Investment Management LLC - ARK Genomic Revolution ETF

Feed

News

Sentiment

Fundamentals

Info

Latest ARKG News

ARKG ARK Investment Management LLC - ARK Genomic Revolution ETF